Every material Form 8-K ResMed filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ResMed reported fiscal first-quarter 2025 results, with revenue up 11% to $1.2 billion, income from operations up 34%, and diluted earnings per share of $2.11, up 42% from $1.49. The company also declared a quarterly cash dividend of $0.53 per share, with a November 7, 2024 record date and December 12, 2024 payment date.
Revenue rose 11% to $1.2 billion; gross margin improved 420 basis points to 58.6%.
Diluted EPS was $2.11 (GAAP) and $2.20 (non-GAAP), versus $1.49 and $1.64 a year earlier.
Quarterly cash dividend of $0.53 per share; ex-dividend date November 6, 2024, payable December 12, 2024.
Operating cash flow was $326 million; the company repurchased $50 million of stock during the quarter.
ResMed expanded its board of directors to 11 and appointed Christopher DelOrefice, executive vice president and chief financial officer of Becton, Dickinson and Company, as a director on August 15, 2024. He will also serve on the board's audit committee and stand for re-election at the annual meeting on November 21, 2024. The filing reports no financial results or guidance changes tied to this appointment.
Board expanded from its prior size to 11 directors; DelOrefice appointed August 15, 2024 at a regularly scheduled board meeting
DelOrefice has been CFO of Becton, Dickinson and Company since September 2021 and previously held roles at Johnson & Johnson
Appointed to the audit committee; term runs to the 2024 annual meeting on November 21, 2024
He will receive director compensation on a pro rata basis and a standard indemnification agreement with ResMed
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ResMed filing is on SEC EDGAR ↗. 8-K briefs of other companies →